Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Free Cash Flow: 2018-2024

Historic Free Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to -$2.5 million.

  • Fulcrum Therapeutics' Free Cash Flow rose 25.70% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 579.50%. This contributed to the annual value of -$2.5 million for FY2024, which is 97.27% up from last year.
  • According to the latest figures from FY2024, Fulcrum Therapeutics' Free Cash Flow is -$2.5 million, which was up 97.27% from -$91.5 million recorded in FY2023.
  • Fulcrum Therapeutics' 5-year Free Cash Flow high stood at -$2.5 million for FY2024, and its period low was -$99.0 million during FY2022.
  • In the last 3 years, Fulcrum Therapeutics' Free Cash Flow had a median value of -$91.5 million in 2023 and averaged -$64.3 million.
  • In the last 5 years, Fulcrum Therapeutics' Free Cash Flow tumbled by 45.81% in 2021 and then skyrocketed by 97.27% in 2024.
  • Yearly analysis of 5 years shows Fulcrum Therapeutics' Free Cash Flow stood at -$55.0 million in 2020, then crashed by 45.81% to -$80.2 million in 2021, then declined by 23.47% to -$99.0 million in 2022, then rose by 7.62% to -$91.5 million in 2023, then soared by 97.27% to -$2.5 million in 2024.